Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Adcirca
Pharma
FDA approves Johnson & Johnson's combo pill Opsynvi for PAH
The FDA has signed off on Opsynvi, a tablet which combines J&J’s Opsumit and United's Adcirca, as a treatment for pulmonary arterial hypertension.
Kevin Dunleavy
Mar 25, 2024 11:05am
In PAH patients, J&J's combo pill Opsynvi increases blood flow
Mar 6, 2023 9:37am
Generics take aim at United's top-selling Remodulin
Mar 27, 2019 12:10pm
